Holen Sie sich die Stockscreener-App
22.33
1.41%
0.31
Handel nachbörslich:
22.33
Alumis Inc Aktie (ALMS) Neueste Nachrichten
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40 - Moomoo
ALMS Maintained by Chardan Capital -- Price Target Raised to $40 - GuruFocus
Alumis price target raised to $40 from $38 at Chardan - TipRanks
Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating - marketscreener.com
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones - Sahm
This Alumis analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] ALUMIS INC. SEC Filing - Stock Titan
[DEF 14A] ALUMIS INC. Definitive Proxy Statement - Stock Titan
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026 - IndexBox
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors? - Sahm
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial - The Clinical Trial Vanguard
HC Wainwright & Co. downgrades Alumis (ALMS) - MSN
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - AOL.com
Morgan Stanley Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $39 - Moomoo
All News about Alumis Inc.Common Stock - The Chronicle-Journal
ALMS Maintained by Guggenheim -- Price Target Raised to $34 - GuruFocus
ALMS Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset - Endpoints News
Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock rating on psoriasis trial data - Investing.com
Why Alumis Inc. Stock Is Sliding After Good News - TipRanks
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Alumis(ALMS.US) to Hold Rating, Maintains Target Price $25 - Moomoo
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Guggenheim raises Alumis stock price target to $34 on psoriasis data By Investing.com - Investing.com South Africa
Guggenheim raises Alumis stock price target to $34 on psoriasis data - Investing.com
Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
HC Wainwright Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects - Fierce Biotech
Alumis (ALMS) Reports Q1 Earnings with Focus on Psoriasis Treatm - GuruFocus
ALMS SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss - Yahoo Finance
ALMS Financials: Income Statement, Balance Sheet & Cash Flow | Alumis Inc - Stock Titan
Alumis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
[10-Q] ALUMIS INC. Quarterly Earnings Report - Stock Titan
Q1 2026 earnings and future milestones announced by ALUMIS INC. - Traders Union
Alumis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Envudeucitinib Phase 3 gains and Q1 2026 results for Alumis (NASDAQ: ALMS) - Stock Titan
Earnings Flash (ALMS) Alumis Inc. Reports Q1 Revenue $1.7M, vs. FactSet Est of $2.5M - marketscreener.com
Press Release: Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements - Moomoo
Alumis psoriasis pill hits 68% PASI 90 in Phase 3 trial - Stock Titan
ALUMIS INC. to present new biomarker data on investigational PsO treatment at Chicago conference - Traders Union
TradingKey - TradingKey
ALMS Stock Price, Quote & Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug - AOL.com
Why Alumis Inc. Shares Are Suddenly Under Pressure - TipRanks
Number of shareholders of Alumis Inc. – NASDAQ:ALMS - TradingView
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):